期刊
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
卷 2, 期 3, 页码 -出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a006486
关键词
-
资金
- Australian-American Fulbright Commission
- American Society for Clinical Oncology
- U.S. National Institutes of Health (NIH) [P01-CA80124, R01-CA85140, R01-CA115767, R01-CA126642]
- Federal Share/NCI Proton Beam Program Income
- National Foundation for Cancer Research
- Department of Defense [W81XWH-10-1-0016]
- AstraZeneca
- Dyax
- MedImmune
- Roche
Pathological angiogenesis-driven byan imbalance of pro-and antiangiogenic signaling-is a hallmark of many diseases, both malignant and benign. Unlike in the healthy adult in which angiogenesis is tightly regulated, such diseases are characterized by uncontrolled new vessel formation, resulting in a microvascular network characterized by vessel immaturity, with profound structural and functional abnormalities. The consequence of these abnormalities is further modification of the microenvironment, often serving to fuel disease progression and attenuate response to conventional therapies. In this article, we present the vascular normalization hypothesis, which states that antiangiogenic therapy, by restoring the balance between pro-and antiangiogenic signaling, can induce a more structurally and functionally normal vasculature in a variety of diseases. We present the preclinical and clinical evidence supporting this concept and discuss how it has contributed to successful treatment of both solid tumors and several benign conditions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据